Sharps Technology (NASDAQ:STSS – Get Free Report ) is one of 234 publicly traded companies in the “Surgical and Medical Devices” industry, but how does it compare to its peers? We compare Sharps Technology to related businesses based on revenue, institutional holdings, analyst recommendations, profitability, valuation, risk and dividend strength.
Analyst Recommendations
Here’s a breakdown of current valuations and target prices for Sharps Technology and its competitors, as reported by MarketBeat.
| Sell ​​rating | Ratings on hold | Purchase Rating | Strong Buy Rating | Evaluation score | |
| Sharps Technology | 0 | 0 | 0 | 0 | N/A |
| Sharps Technology Competitors | 1705 | 4504 | 8676 | 235 | 2.49 |
As a group, “Surgical & Medical Devices” companies have an upside potential of 25.32%. Considering the higher upside potential of Sharps Technology’s peers, analysts clearly believe that Sharps Technology is underperforming its peers in terms of growth.
Insider and Institutional Ownership
17.2% of Sharps Technology’s shares are held by institutional investors. In comparison, 48.2% of all “Surgical & Medical Devices” companies’ shares are held by institutional investors. 12.6% of Sharps Technology’s shares are held by insiders. In comparison, 15.4% of all “Surgical & Medical Devices” companies’ shares are held by insiders. A high level of institutional ownership suggests that endowments, hedge funds and large asset managers believe that the company will outperform the market in the long term.
Revenue and Ratings
This table compares Sharps Technology’s total revenue, earnings per share, and valuation with its competitors.
| Earnings | Net income | Price Earnings Ratio | |
| Sharps Technology | N/A | -$9.84 million | -0.44 |
| Sharps Technology Competitors | $1.03 billion | $3.51 million | -4,694.91 |
Sharps Technology’s peers have higher revenues and profits than Sharps Technology, and Sharps Technology is trading at a higher price-to-earnings multiple than its peers, indicating that its stock is currently more expensive than its peers.
Profitability
This table compares the net profit margin, return on equity, and return on assets of Sharps Technology and its competitors.
| Net income | Return on Equity | Return on Assets | |
| Sharps Technology | N/A | -102.25% | -72.97% |
| Sharps Technology Competitors | -673.57% | -130.38% | -27.83% |
Volatility and Risk
Sharps Technology’s beta is 1.24, meaning that the company’s share price is 24% more volatile than the S&P 500. In comparison, Sharps Technology’s peers have a beta of 0.98, meaning that the company’s average share price is 2% less volatile than the S&P 500.
summary
Sharps Technology’s peers outperformed Sharps Technology in six of the ten factors compared.
About Sharps Technology
(Get your free report)
Sharps Technology, Inc., a medical device manufacturer, researches, designs, develops, manufactures, distributes and sells safety syringe products in the United States. The company offers Sharps Provensa, a very low-waste syringe that can be used to administer a variety of vaccines and injectable medications. Sharps Technology, Inc. was founded in 2017 and is based in Melville, New York.
Receive Sharps Technology news and reviews daily –Enter your email address below to receive a concise summary of the latest news and analyst ratings on Sharps Technology and related companies every day with MarketBeat.com’s free email newsletter.
